Literature DB >> 28874895

Wherein the authors attempt to minimize the confusion generated by their study "Breast cancer mortality after a diagnosis of ductal carcinoma in situ" by several commentators who disagree with them and a few who don't: a qualitative study.

S A Narod1,2, H Ahmed1,3, V Sopik1,3.   

Abstract

Entities:  

Year:  2017        PMID： 28874895      PMCID： PMC5576464          DOI： 10.3747/co.24.3626

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  52 in total

1.  A Call for Change in the Diagnosis and Treatment of Patients with Ductal Carcinoma In Situ: An Opportunity to Minimize Overdiagnosis and Overtreatment.

Authors:  Shahla Masood
Journal:  Breast J       Date:  2015 Nov-Dec       Impact factor: 2.431

2.  Rethinking the Standard for Ductal Carcinoma In Situ Treatment.

Authors:  Laura Esserman; Christina Yau
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

3.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

4.  Ductal carcinoma in situ: How much is too much?

Authors:  Keerthi Gogineni
Journal:  Cancer       Date:  2016-05-31       Impact factor: 6.860

Review 5.  Updates in the treatment of ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Thorsten Kühn
Journal:  Curr Opin Obstet Gynecol       Date:  2016-02       Impact factor: 1.927

6.  Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Patricia A Cronin; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2016-05-19       Impact factor: 5.344

Review 7.  Is the false-positive rate in mammography in North America too high?

Authors:  Michelle T Le; Carmel E Mothersill; Colin B Seymour; Fiona E McNeill
Journal:  Br J Radiol       Date:  2016-06-08       Impact factor: 3.039

Review 8.  Benefits and Harms of Breast Cancer Screening: A Systematic Review.

Authors:  Evan R Myers; Patricia Moorman; Jennifer M Gierisch; Laura J Havrilesky; Lars J Grimm; Sujata Ghate; Brittany Davidson; Ranee Chatterjee Mongtomery; Matthew J Crowley; Douglas C McCrory; Amy Kendrick; Gillian D Sanders
Journal:  JAMA       Date:  2015-10-20       Impact factor: 56.272

9.  Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention.

Authors:  Niamh Buckley; David Boyle; Darragh McArt; Gareth Irwin; D Paul Harkin; Tong Lioe; Stephen McQuaid; Jacqueline A James; Perry Maxwell; Peter Hamilton; Paul B Mullan; Manuel Salto-Tellez
Journal:  Oncotarget       Date:  2015-12-22

10.  Early dissemination seeds metastasis in breast cancer.

Authors:  Hedayatollah Hosseini; Milan M S Obradović; Martin Hoffmann; Kathryn L Harper; Maria Soledad Sosa; Melanie Werner-Klein; Lahiri Kanth Nanduri; Christian Werno; Carolin Ehrl; Matthias Maneck; Nina Patwary; Gundula Haunschild; Miodrag Gužvić; Christian Reimelt; Michael Grauvogl; Norbert Eichner; Florian Weber; Andreas D Hartkopf; Florin-Andrei Taran; Sara Y Brucker; Tanja Fehm; Brigitte Rack; Stefan Buchholz; Rainer Spang; Gunter Meister; Julio A Aguirre-Ghiso; Christoph A Klein
Journal:  Nature       Date:  2016-12-14       Impact factor: 49.962
View more
  2 in total

1.  Ductal carcinoma in situ is presumably not a metastatic disease: a reply to "Commentary: Wherein the authors attempt to minimize the confusion generated by their study 'Breast cancer mortality after a diagnosis of ductal carcinoma in situ' by several commentators who disagree with them and a few who don't: a qualitative study".

Authors:  Brett T Snodgrass
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

Review 2.  Is invasion a necessary step for metastases in breast cancer?

Authors:  Steven A Narod; Victoria Sopik
Journal:  Breast Cancer Res Treat       Date:  2018-01-20       Impact factor: 4.872
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.